The purpose of this study is to determine the feasibility of chemotherapy, consisting of docetaxel, cisplatin and capecitabine given prior to surgery for stomach cancer. Furthermore, an extended type of removal of lymph nodes will be implemented.

No prior radio- or chemotherapy conflicting with the treatment of gastric cancer

Haematology/Renal function/Liver function within designated range

Patient's consent form obtained, signed and dated before beginning specific protocol procedures

absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

before patient registration/randomization, written informed consent must be given according to GCP, WMO and local regulations.

Exclusion Criteria:

Previous or other current malignancies, with the exception of adequately treated in situ carcinoma of the cervix uteri or non-melanoma skin cancer

Other current serious illness or medical conditions

Severe cardiac illness (NYHA class III-IV)

Significant neurologic or psychiatric disorders

Uncontrolled infections

Active DIC

Other serious underlying medical conditions that could impair the ability of the patient to participate in the study

Known hypersensitivity to docetaxel (or any drug formulated with Polysorbate-80), or cisplatin or capecitabine or 5-FU

Definite contraindications for the use of corticosteroids

Use of immunosuppressive or antiviral drugs

Any other experimental drugs within a 4-week period prior to start of neoadjuvant chemotherapy and throughout the study period

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01517009